- Home
- DPG vs NNNN Comparison
DPG vs NNNN Comparison
Compare DPG & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPG
- NNNN
- Stock Information
- Founded
- DPG 2011
- NNNN 2021
- Country
- DPG United States
- NNNN Germany
- Employees
- DPG N/A
- NNNN N/A
- Industry
- DPG Trusts Except Educational Religious and Charitable
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DPG Finance
- NNNN Health Care
- Exchange
- DPG Nasdaq
- NNNN Nasdaq
- Market Cap
- DPG 450.4M
- NNNN 369.6M
- IPO Year
- DPG N/A
- NNNN 2025
- Fundamental
- Price
- DPG $12.47
- NNNN $49.26
- Analyst Decision
- DPG
- NNNN
- Analyst Count
- DPG 0
- NNNN 0
- Target Price
- DPG N/A
- NNNN N/A
- AVG Volume (30 Days)
- DPG 150.1K
- NNNN 220.1K
- Earning Date
- DPG 01-01-0001
- NNNN 01-01-0001
- Dividend Yield
- DPG 9.09%
- NNNN N/A
- EPS Growth
- DPG N/A
- NNNN N/A
- EPS
- DPG N/A
- NNNN 0.06
- Revenue
- DPG N/A
- NNNN $8,185,146.00
- Revenue This Year
- DPG N/A
- NNNN N/A
- Revenue Next Year
- DPG N/A
- NNNN N/A
- P/E Ratio
- DPG N/A
- NNNN $908.77
- Revenue Growth
- DPG N/A
- NNNN 21.95
- 52 Week Low
- DPG $7.90
- NNNN $5.18
- 52 Week High
- DPG $13.58
- NNNN $53.11
- Technical
- Relative Strength Index (RSI)
- DPG 60.67
- NNNN N/A
- Support Level
- DPG $12.13
- NNNN N/A
- Resistance Level
- DPG $12.45
- NNNN N/A
- Average True Range (ATR)
- DPG 0.17
- NNNN 0.00
- MACD
- DPG 0.01
- NNNN 0.00
- Stochastic Oscillator
- DPG 65.87
- NNNN 0.00
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting from a high level of current income, with an emphasis on providing tax-advantaged dividend income.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.